Reference List

1. Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7(4 Pt 1):1497-507. doi: 10.1111/j.1743-6109.2010.01806.x [published Online First: 20100303]

2. Gittelman M, McMahon CG, Rodriguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64(5):594-603. doi: 10.1111/j.1742-1241.2010.02358.x

3. Tienforti D, Felzani G, Di Pasquale AB, et al. Which PDE5 inhibitor is the most effective in the treatment of erectile dysfunction in men with spinal cord injury? A systematic review and network meta-analysis. Andrology 2025;13(2):314-22. doi: 10.1111/andr.13642 [published Online First: 20240330]

4. Stridh A, Ponten M, Arver S, et al. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3(3):e201423. doi: 10.1001/jamanetworkopen.2020.1423 [published Online First: 20200302]

5. Napolitano L, Fusco GM, Cirillo L, et al. Erectile dysfunction and mobile phone applications: Quality, content and adherence to European Association guidelines on male sexual dysfunction. Arch Ital Urol Androl 2022;94(2):211-16. doi: 10.4081/aiua.2022.2.211 [published Online First: 20220630]

6. Chung E, Lowy M, Gillman M, et al. Urological Society of Australia and New Zealand (USANZ) and Australasian Chapter of Sexual Health Medicine (AChSHM) for the Royal Australasian College of Physicians (RACP) clinical guidelines on the management of erectile dysfunction. Med J Aust 2022;217(6):318-24. doi: 10.5694/mja2.51694 [published Online First: 20220904]

7. Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. J Sex Med 2018;15(4):430-57. doi: 10.1016/j.jsxm.2018.01.023 [published Online First: 20180314]

8. Bella AJ, Lee JC, Carrier S, et al. 2015 CUA Practice guidelines for erectile dysfunction. Can Urol Assoc J 2015;9(1-2):23-9. doi: 10.5489/cuaj.2699

9. Zhang X, Pan J, Xu R, et al. Erectile dysfunction associated with prostate cancer treatment and therapeutic advances: a narrative review. Transl Androl Urol 2024;13(11):2625-43. doi: 10.21037/tau-24-514 [published Online First: 20241128]

10. Allen MS, Walter EE. Erectile Dysfunction: An Umbrella Review of Meta-Analyses of Risk-Factors, Treatment, and Prevalence Outcomes. J Sex Med 2019;16(4):531-41. doi: 10.1016/j.jsxm.2019.01.314 [published Online First: 20190302]

11. Francis SH, Corbin JD. PDE5 inhibitors: targeting erectile dysfunction in diabetics. Curr Opin Pharmacol 2011;11(6):683-8. doi: 10.1016/j.coph.2011.08.004 [published Online First: 20110915]

12. Francis SH, Corbin JD. Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 2005;1(2):283-93. doi: 10.1517/17425255.1.2.283

13. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004;16 Suppl 1:S4-7. doi: 10.1038/sj.ijir.3901205

14. Corona G, Rastrelli G, Burri A, et al. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. Andrology 2016;4(6):1002-09. doi: 10.1111/andr.12255 [published Online First: 20160916]

15. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T 2013;38(7):407-19.

16. Chung E, Argent C, Strange G. Pharmacokinetics of an oral versus intranasal delivered formulation of the phosphodiesterase type 5 inhibitor vardenafil in healthy men - a phase 1, randomized, open-label, single-dose, two-period, two-treatment, cross-over study. Eur J Pharm Sci 2025;213:107226. doi: 10.1016/j.ejps.2025.107226 [published Online First: 20250807]

17. Aslan Y, Tuncel A, Aydin O, et al. The association between Erection Hardness Grading Scale and International Index of Erectile Function in men with erectile dysfunction treated with sildenafil citrate. Urol Int 2011;86(4):434-8. doi: 10.1159/000324100 [published Online First: 20110331]

18. Muller MJ, Ruof J, Graf-Morgenstern M, et al. Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry 2001;34(3):91-5. doi: 10.1055/s-2001-14277

19. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13(4):192-9. doi: 10.1038/sj.ijir.3900713

20. Chen Q, Mao Y, Zhou H, et al. Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. Int J Clin Pract 2022;2022:9298483. doi: 10.1155/2022/9298483 [published Online First: 20221103]

21. Conaglen HM, Conaglen JV. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J Sex Med 2012;9(3):857-65. doi: 10.1111/j.1743-6109.2011.02625.x [published Online First: 20120112]

22. Kim SC, Lee YS, Seo KK, et al. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res 2014;26(3):87-93. doi: 10.1038/ijir.2013.41 [published Online First: 20131205]